Vita-Solar Biotechnology

Vitalion, also known as Vita-Solar Biotechnology, is a clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough therapies for aging-related and degenerative diseases. The company was co-founded by Dr. Xiaodong Wang, a member of the National Academy of Sciences and co-founder of BeiGene, and Dr. Zhiyuan Zhang. Vitalion's research focuses on the mechanisms of programmed cell death, specifically necroptosis and neuroinflammation, to address high unmet medical needs in neurology and immunology. Its lead candidate, VT-101, is a potent, brain-penetrant RIPK1 inhibitor currently being evaluated in clinical trials for Amyotrophic Lateral Sclerosis (ALS). The company is backed by a syndicate of premier global investors and operates out of Beijing, China.